GeneOne Life Science, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 10,274.11 million compared to KRW 8,575.88 million a year ago. Net loss was KRW 10,973.53 million compared to KRW 6,284.07 million a year ago. Basic loss per share from continuing operations was KRW 142 compared to KRW 93.3333 a year ago. Diluted loss per share from continuing operations was KRW 142 compared to KRW 93.3333 a year ago. Basic loss per share was KRW 141 compared to KRW 140 a year ago.
For the six months, sales was KRW 18,035.49 million compared to KRW 13,853.3 million a year ago. Net loss was KRW 15,595.36 million compared to KRW 8,114.02 million a year ago. Basic loss per share from continuing operations was KRW 201 compared to KRW 120.6667 a year ago. Diluted loss per share from continuing operations was KRW 201 compared to KRW 120.6667 a year ago. Basic loss per share was KRW 201 compared to KRW 181 a year ago.